(Q37756963)

22 August 2017

1 reference

title

Treatment of dyslipidemia in HIV-infected patients (English)

1 reference

22 August 2017

1 reference

Rajagopal V Sekhar

1

1 reference

22 August 2017

Ashok Balasubramanyam

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

11

1 reference

22 August 2017

page(s)

1845-1854

1 reference

Lipodystrophy in patients naive to HIV protease inhibitors

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Lipid abnormalities in a never-treated HIV-1 subtype C-infected African population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Nonalcoholic fatty liver disease among HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Metabolic basis of HIV-lipodystrophy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Alterations in lipid kinetics in men with HIV-dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Hypertriglyceridemia in the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

HIV infection and high density lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Human immunodeficiency virus impairs reverse cholesterol transport from macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Are HIV positive patients resistant to statin therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Characterization of a new circulating recombinant form comprising HIV-1 subtypes C and B in southern Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Effect of extended-release niacin on hormone-sensitive lipase and lipoprotein lipase in patients with HIV-associated lipodystrophy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487484

10.1517/14656566.2010.487484

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference